Discovery of a drug candidate for GLIS3-associated diabetes
GLIS3 mutations are associated with type 1, type 2, and neonatal diabetes. Here, the authors generate mono-hormonal glucose-responding pancreatic β-like cells in vitro and through a screen identify a drug that rescues pancreatic β-like cell death in GLIS3 mutants by inhibiting the abnormally activat...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-04918-x |